Holen Sie sich die Stockscreener-App
9.46
5.49%
-0.55
Handel nachbörslich:
9.70
0.24
+2.54%
Schlusskurs vom Vortag:
$10.01
Offen:
$9.82
24-Stunden-Volumen:
10.14M
Relative Volume:
1.90
Marktkapitalisierung:
$6.75B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
1.6743
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
-8.86%
1M Leistung:
-8.33%
6M Leistung:
-16.87%
1J Leistung:
-17.81%
1-Tages-Spanne:
$9.42
$9.91
1-Wochen-Bereich:
$9.42
$10.22
52-Wochen-Spanne:
$9.42
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
9.46 | 6.75B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Yahoo Finance
(ROIV) Trading Signals - Stock Traders Daily
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
Genevant and Arbutus initiate patent lawsuit against Moderna - The Pharma Letter
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Trend Tracker for (ROIV) - Stock Traders Daily
Principal Financial Group Inc. Lowers Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Handelsbanken Fonder AB Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Net worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governor - Times of India
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - The Manila Times
Early Warning Report Issued Pursuant to National Instrument 62?103: Roivant announces Resignation and Replacement of Arbutus Board - Lelezard
Roivant Sciences president Eric Venker sells $1.07 million in shares - Investing.com India
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat
Long Term Trading Analysis for (ROIV) - Stock Traders Daily
Roivant Sciences’ chief accounting officer sells $2.37 million in shares - Investing.com India
Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada
Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):